rs200092211

Variant summary

Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2

The NM_000726.5(CACNB4):​c.5C>T​(p.Ser2Phe) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000877 in 1,533,242 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.00091 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00087 ( 1 hom. )

Consequence

CACNB4
NM_000726.5 missense

Scores

2
4
13

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:5B:8

Conservation

PhyloP100: 2.67
Variant links:
Genes affected
CACNB4 (HGNC:1404): (calcium voltage-gated channel auxiliary subunit beta 4) This gene encodes a member of the beta subunit family of voltage-dependent calcium channel complex proteins. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. Various versions of each of these subunits exist, either expressed from similar genes or the result of alternative splicing. The protein encoded by this locus plays an important role in calcium channel function by modulating G protein inhibition, increasing peak calcium current, controlling the alpha-1 subunit membrane targeting and shifting the voltage dependence of activation and inactivation. Certain mutations in this gene have been associated with idiopathic generalized epilepsy (IGE), juvenile myoclonic epilepsy (JME), and episodic ataxia, type 5. [provided by RefSeq, Aug 2016]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -9 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.016155422).
BP6
Variant 2-152099007-G-A is Benign according to our data. Variant chr2-152099007-G-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 193120.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=2, Benign=3, Uncertain_significance=5}. Variant chr2-152099007-G-A is described in Lovd as [Likely_benign].
BS2
High AC in GnomAd4 at 138 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CACNB4NM_000726.5 linkc.5C>T p.Ser2Phe missense_variant Exon 1 of 14 ENST00000539935.7 NP_000717.2 O00305-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CACNB4ENST00000539935.7 linkc.5C>T p.Ser2Phe missense_variant Exon 1 of 14 1 NM_000726.5 ENSP00000438949.1 O00305-1

Frequencies

GnomAD3 genomes
AF:
0.000907
AC:
138
AN:
152112
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000121
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00209
Gnomad ASJ
AF:
0.00778
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000414
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00318
Gnomad NFE
AF:
0.00104
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.00145
AC:
195
AN:
134704
Hom.:
0
AF XY:
0.00121
AC XY:
88
AN XY:
72796
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00194
Gnomad ASJ exome
AF:
0.00996
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.000240
Gnomad FIN exome
AF:
0.0000663
Gnomad NFE exome
AF:
0.00114
Gnomad OTH exome
AF:
0.00458
GnomAD4 exome
AF:
0.000873
AC:
1206
AN:
1381012
Hom.:
1
Cov.:
31
AF XY:
0.000889
AC XY:
606
AN XY:
681524
show subpopulations
Gnomad4 AFR exome
AF:
0.000133
Gnomad4 AMR exome
AF:
0.00176
Gnomad4 ASJ exome
AF:
0.0100
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.000299
Gnomad4 FIN exome
AF:
0.0000204
Gnomad4 NFE exome
AF:
0.000732
Gnomad4 OTH exome
AF:
0.00145
GnomAD4 genome
AF:
0.000907
AC:
138
AN:
152230
Hom.:
0
Cov.:
32
AF XY:
0.000954
AC XY:
71
AN XY:
74426
show subpopulations
Gnomad4 AFR
AF:
0.000120
Gnomad4 AMR
AF:
0.00209
Gnomad4 ASJ
AF:
0.00778
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.000415
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00104
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.00150
Hom.:
0
Bravo
AF:
0.000948
TwinsUK
AF:
0.000539
AC:
2
ALSPAC
AF:
0.000259
AC:
1
ExAC
AF:
0.000728
AC:
77

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:5Benign:8
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:2Benign:3
Dec 12, 2017
GeneDx
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The S2F variant of unknown significance has not been published as a pathogenic variant, nor has it been reported as a benign polymorphism to our knowledge. The 1000 Genomes Project reports S2F was observed in 1/214 alleles (0.5%) from individuals of Italian background (McVean et al., 2012). The S2F variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution alters a highly conserved position in the N-terminal region of the CACNB4 protein, and in silico analysis predicts this variant is probably damaging to the protein structure/function. However, to date only a small number of substitutions in CACNB4 have been published in association with epilepsy, and no pathogenic variants have been reported in the N-terminal region of the protein (Escayg et al., 2000; Ohmori et al., 2008). Therefore, based on the currently available information, it is unclear whether S2F is a pathogenic or a rare benign variant. -

-
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Aug 13, 2014
Eurofins Ntd Llc (ga)
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Oct 01, 2022
CeGaT Center for Human Genetics Tuebingen
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

CACNB4: BS1, BS2 -

not specified Uncertain:1Benign:1
Apr 07, 2021
Athena Diagnostics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Aug 04, 2015
Genetic Services Laboratory, University of Chicago
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Epilepsy, idiopathic generalized, susceptibility to, 9 Uncertain:1
Mar 31, 2016
Mayo Clinic Laboratories, Mayo Clinic
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Episodic ataxia type 5;C2750887:Epilepsy, idiopathic generalized, susceptibility to, 9 Uncertain:1
May 23, 2017
Fulgent Genetics, Fulgent Genetics
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Juvenile myoclonic epilepsy Benign:1
Jun 14, 2016
Illumina Laboratory Services, Illumina
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

CACNB4-related disorder Benign:1
Nov 26, 2019
PreventionGenetics, part of Exact Sciences
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Episodic ataxia type 5 Benign:1
Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Idiopathic generalized epilepsy Benign:1
Oct 23, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.14
BayesDel_addAF
Benign
-0.29
T
BayesDel_noAF
Benign
-0.21
CADD
Uncertain
24
DANN
Uncertain
0.98
DEOGEN2
Benign
0.14
T;.;.;.
Eigen
Benign
-0.17
Eigen_PC
Benign
-0.23
FATHMM_MKL
Benign
0.56
D
LIST_S2
Benign
0.60
T;T;T;T
M_CAP
Pathogenic
0.77
D
MetaRNN
Benign
0.016
T;T;T;T
MetaSVM
Benign
-0.68
T
MutationAssessor
Benign
0.81
L;.;.;L
PrimateAI
Uncertain
0.76
T
PROVEAN
Benign
-0.61
N;.;.;N
REVEL
Uncertain
0.33
Sift
Pathogenic
0.0
D;.;.;D
Sift4G
Uncertain
0.0050
D;.;.;D
Polyphen
0.97
D;.;.;.
Vest4
0.47
MVP
0.87
MPC
1.7
ClinPred
0.18
T
GERP RS
2.7
Varity_R
0.22
gMVP
0.43

Splicing

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs200092211; hg19: chr2-152955521; API